Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Sanofi
|
| gptkbp:acquisition |
acquired by Sanofi
|
| gptkbp:advocates_for |
supports patient advocacy initiatives
|
| gptkbp:business_model |
focused on innovative therapies
|
| gptkbp:can_lead_to |
Teplizumab for Type 1 diabetes
|
| gptkbp:ceo |
gptkb:Ashleigh_Palmer
|
| gptkbp:clinical_trial |
conducts clinical research studies
conducts clinical trials for new therapies Phase 3 trial for Teplizumab clinical-stage biopharmaceutical company defines clinical endpoints for trials generates clinical data has a dedicated clinical research team |
| gptkbp:collaborations |
engages in research collaborations
collaborated with academic institutions |
| gptkbp:committee |
has a scientific advisory board
|
| gptkbp:community_engagement |
engages with patient communities
|
| gptkbp:financial_performance |
monitors financial performance
|
| gptkbp:focus |
autoimmune diseases
|
| gptkbp:founded |
gptkb:2016
|
| gptkbp:founder |
gptkb:Ashleigh_Palmer
|
| gptkbp:governed_by |
gptkb:Dr._David_A._Harlan
|
| gptkbp:headquarters |
gptkb:Red_Bank,_New_Jersey
|
| gptkbp:healthcare |
pursues therapeutic innovation in autoimmune diseases
|
| https://www.w3.org/2000/01/rdf-schema#label |
Provention Bio
|
| gptkbp:innovation |
drives innovation in treatment approaches
|
| gptkbp:investment |
gptkb:Sanofi
Venture capital firms maintains investor relations |
| gptkbp:language_of_instruction |
multiple product candidates
|
| gptkbp:leadership |
experienced leadership team
|
| gptkbp:market |
biopharmaceutical market
establishes market presence in the biopharmaceutical industry |
| gptkbp:marketing_strategy |
develops market strategies for products
implements business strategies for growth |
| gptkbp:mission |
dedicated to preventing autoimmune diseases
transform the treatment of autoimmune diseases |
| gptkbp:partnership |
collaboration with Sanofi
|
| gptkbp:partnerships |
establishes partnerships with healthcare organizations
forms healthcare partnerships for research. |
| gptkbp:products |
gptkb:Teplizumab
focuses on product development for unmet needs |
| gptkbp:receives_funding_from |
receives research funding from various sources
raised significant venture capital completed a public offering |
| gptkbp:regulatory_compliance |
FDA approval for Teplizumab
submits regulatory filings |
| gptkbp:research |
gptkb:Dr._Jennifer_L._Gunter
conducts scientific research in immunology |
| gptkbp:research_areas |
immunology
novel therapeutic approaches develops therapeutic candidates for autoimmune diseases |
| gptkbp:research_focus |
prevention of Type 1 diabetes
|
| gptkbp:safety_features |
prioritizes patient safety in trials
|
| gptkbp:side_effect |
strives to have a positive healthcare impact
|
| gptkbp:symbol |
PRVB
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:treatment |
aims to improve clinical outcomes for patients
|
| gptkbp:type |
gptkb:Company
|
| gptkbp:website |
www.proventionbio.com
|